ALT

3.06

1.32% 0.04

시간 외 거래: 3.02 -0.04 -1.31%

알티뮨 (ALT)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할 배당 이력

전일 마감가:

$3.02

열려 있는:

$3.08

하루 거래량:

3.46M

Relative Volume:

0.86

시가총액:

$594.73M

수익:

$41,000

순이익/손실:

$-88.09M

주가수익비율:

-3.0136

EPS:

-1.0154

순현금흐름:

$-67.55M

1주 성능:

+11.68%

1개월 성능:

-8.38%

6개월 성능:

-18.40%

1년 성능:

-43.65%

1일 변동 폭

$3.00

$3.15

1주일 범위

$2.56

$3.15

52주 변동 폭

$2.56

$7.73

알티뮨 Stock (ALT) Company Profile

명칭

Altimmune Inc

부문

Healthcare (1106)

산업

Biotechnology (615)

전화

(240) 654-1450

주소

910 CLOPPER ROAD, GAITHERSBURG, MD

직원

트위터

다음 수익 날짜

2026-05-12

최신 SEC 제출 서류

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
ALT Altimmune Inc	3.06	586.95M	41,000	-88.09M	-67.55M	-1.0154
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

알티뮨 Stock (ALT) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-04-24	업그레이드	Goldman	Sell → Neutral
2026-03-18	개시	Truist	Buy
2026-01-28	개시	Barclays	Overweight
2025-07-10	재개	Goldman	Sell
2025-02-28	개시	William Blair	Mkt Perform
2025-01-08	개시	Stifel	Buy
2024-11-12	개시	UBS	Buy
2024-04-29	다운그레이드	Guggenheim	Buy → Neutral
2024-01-24	개시	Goldman	Neutral
2023-03-22	다운그레이드	Goldman	Buy → Neutral
2022-12-01	개시	Goldman	Buy
2021-12-29	재개	Jefferies	Buy
2021-06-02	개시	H.C. Wainwright	Buy
2021-02-11	개시	Guggenheim	Buy
2020-12-14	개시	Jefferies	Buy
2020-11-12	재확인	B. Riley Securities	Buy
2020-09-25	개시	B. Riley FBR	Buy
2020-08-14	개시	Evercore ISI	Outperform
2020-07-31	개시	Piper Sandler	Overweight
2020-07-28	개시	JMP Securities	Mkt Outperform
2020-02-24	재개	ROTH Capital	Buy
2019-07-19	개시	ROTH Capital	Buy
2017-10-09	개시	Piper Jaffray	Overweight

모두보기

알티뮨 주식(ALT)의 최신 뉴스

03:14 AM

LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN

03:14 AM

05:27 AM

ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan

05:27 AM

May 03, 2026

MSN Money - MSN

May 03, 2026

May 02, 2026

Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com

May 02, 2026

May 01, 2026

Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan

May 01, 2026

Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan

May 01, 2026

Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan

May 01, 2026

Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan

May 01, 2026

Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan

May 01, 2026

Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan

May 01, 2026

[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan

May 01, 2026

Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan

May 01, 2026

RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan

May 01, 2026

Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan

May 01, 2026

Dilution fears return: Why ALT stock is getting hit again - MSN

May 01, 2026

ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill

May 01, 2026

Apr 30, 2026

Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan

Apr 30, 2026

ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView

Apr 30, 2026

Altimmune a new buy at Truist on pemvidutide promise - MSN

Apr 30, 2026

Apr 29, 2026

ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN

Apr 29, 2026

Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union

Apr 29, 2026

Apr 28, 2026

Altimmune catalysts: 2026 data readouts and financing risks - MSN

Apr 28, 2026

Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter

Apr 28, 2026

Apr 27, 2026

Altimmune closes $225M financing for MASH drug trial - Investing.com UK

Apr 27, 2026

Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals

Apr 27, 2026

Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz

Apr 27, 2026

Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia

Apr 27, 2026

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail

Apr 27, 2026

Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey

Apr 26, 2026

알티뮨 (ALT) 재무 분석

매출

순이익

현금흐름

주당 순 이익

ROIV

$28.32

0.14%

RPRX

$50.44

0.48%

BNTX

$95.50

3.88%

INSM

$139.44

0.41%

RVMD

$147.21

0.47%

ONC

$297.49

0.12%

알티뮨 (ALT)

알티뮨 Stock (ALT) Company Profile

Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC

알티뮨 Stock (ALT) Upgrades & Downgrades

알티뮨 주식(ALT)의 최신 뉴스

LULU, LCID, ALT stocks hit 52-week lows today: What's driving the selloff? - MSN

ALT SEC FilingsAltimmune 10-K, 10-Q, 8-K Forms - Stock Titan

MSN Money - MSN

Altimmune Stock Dips After $225M Offering Reshapes Funding Outlook - timothysykes.com

Viking Global (NASDAQ: ALT) reports 6.7% Altimmune stake, 6.7M warrants - Stock Titan

Chen Yu and TCG funds report 20M ALT stake (NASDAQ: ALT) - Stock Titan

Altimmune (ALT) director Teri Lawver granted 48,800 stock options at $2.82 - Stock Titan

Altimmune (ALT) awards 48,800 stock options to director Catherine Sohn - Stock Titan

Altimmune (ALT) director receives 48,800-share stock option grant - Stock Titan

Altimmune (ALT) director Klaus Schafer awarded 48,800 stock options at $2.82 - Stock Titan

[Form 4] Altimmune, Inc. Insider Trading Activity - Stock Titan

Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price - Stock Titan

RA Capital, affiliates report 13M shares in Altimmune (ALT) — 6.5% stake - Stock Titan

Altimmune (ALT) director receives grant of 48,800 stock options - Stock Titan

Dilution fears return: Why ALT stock is getting hit again - MSN

ALT Forecast, Price Target & Analyst Ratings | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill

Deep Track reports 9.99% stake in Altimmune (ALT) via warrants and shares - Stock Titan

ALT Q1'26 Earnings: revenue estimate is 1.11K USD - TradingView

Altimmune a new buy at Truist on pemvidutide promise - MSN

ALT stock drops on wider-than-expected Q4 loss: Retail voices hopes for deal to alleviate cash concerns - MSN

Altimmune urges earlier clinical action on alcohol use disorder and liver disease link - Traders Union

Altimmune catalysts: 2026 data readouts and financing risks - MSN

Altimmune secures $225 million financing for pemvidutide development - The Pharma Letter

Altimmune closes $225M financing for MASH drug trial - Investing.com UK

Altimmune secures $225M to test GLP-1 in liver disease, eyes first commercial product launch - The Business Journals

Altimmune Closes $225 Million Oversubscribed Offering to Fund Phase 3 MASH Trial - citybiz

Altimmune closes $225M financing for MASH drug trial By Investing.com - Investing.com Australia

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities - The Globe and Mail

Altimmune raises $225M to fund late-stage MASH drug trial - Stock Titan

Altimmune prices $75M direct offering - MSN

Altimmune shares slide after $75 million registered direct offering - MSN

Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock - Insider Monkey

알티뮨 (ALT) 재무 분석

매출

순이익

현금흐름

주당 순 이익

ALT과 유사한 종목